Correction: Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade

Correction: Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade

Bibliographic Details
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-01-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/12/1/e004762corr1.full

Similar Items

Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade
by: Jun Zhang, et al.
Published: (2022-06-01)

1444 Pharmacologic LDH inhibition redirects intratumoral glucose consumption and improves response to CTLA-4 blockade
by: Jedd D Wolchok, et al.
Published: (2023-11-01)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4<sup>+</sup> T Cells
by: Reem Saleh, et al.
Published: (2019-10-01)

Expression of inhibitory receptors PD-1, CTLA-4, and Tim-3 by peripheral T cells during pregnancy
by: E. A. Smetanenko, et al.
Published: (2022-10-01)

Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors
by: GAN Zi-ying, TANG Hui
Published: (2022-04-01)

CORRECTION NOTICE “Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma”
Published: (2022-12-01)

Correction: Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors
Published: (2023-02-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01)

Correction: Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer
Published: (2024-01-01)

The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade
by: Sajad Najafi, et al.
Published: (2023-05-01)

Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies
by: Shashi Gujar, et al.
Published: (2018-08-01)

Remodeling the tumor-immune microenvironment by anti-CTLA4 blockade enhanced subsequent anti-PD-1 efficacy in advanced nasopharyngeal carcinoma
by: Yuxiang Ma, et al.
Published: (2024-03-01)

Intratumoral Delivery of Interleukin 9 via Oncolytic Vaccinia Virus Elicits Potent Antitumor Effects in Tumor Models
by: Junjie Ye, et al.
Published: (2024-02-01)

Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors
by: Jérémy Béguin, et al.
Published: (2023-09-01)

Oncolytic vaccinia virus injected intravenously sensitizes pancreatic neuroendocrine tumors and metastases to immune checkpoint blockade
by: Mitsuko Inoue, et al.
Published: (2022-03-01)

Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry
by: Filipa Godoy-Vitorino, et al.
Published: (2022-07-01)

PD-1/CTLA-4 blockade leads to expansion of CD8+PD-1int TILs and results in tumor remission in experimental liver cancer
by: Sandra Bufe, et al.
Published: (2022-10-01)

Defects in intratumoral arginine metabolism attenuate the replication and therapeutic efficacy of oncolytic myxoma virus
by: Eric Bartee, et al.
Published: (2023-06-01)

CaCO3 powder-mediated biomineralization of antigen nanosponges synergize with PD-1 blockade to potentiate anti-tumor immunity
by: Runping Su, et al.
Published: (2023-04-01)

Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma
by: Xia Ran, et al.
Published: (2020-12-01)

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
by: Jeffrey Schlom, et al.
Published: (2022-06-01)

PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer
by: Peng Liu, et al.
Published: (2022-12-01)

High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer
by: Baran Mollavelioglu, et al.
Published: (2022-10-01)

Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade
by: Fateme Safaeifard, et al.
Published: (2022-11-01)

Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer
by: Hiroyuki Araki, et al.
Published: (2022-12-01)

Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors
by: Andrew Coxon, et al.
Published: (2022-12-01)

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
by: Firas Y. Kreidieh, et al.
Published: (2023-07-01)

Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer
by: Sharad Goyal, et al.
Published: (2023-07-01)

Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing
by: Katrin Goepfert, et al.
Published: (2019-05-01)

Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression
by: Simon Gebremeskel, et al.
Published: (2022-03-01)

Clinical Application of Immune Checkpoint Inhibitors CTLA-4 in Solid Tumors
by: LI Tao, et al.
Published: (2023-05-01)

CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade
by: Julie Vackova, et al.
Published: (2021-04-01)

CTLA-4 blockade in the treatment of colorectal cancer with microsatellite instability
by: Diana Russo, et al.
Published: (2021-03-01)

Long-Term Response to PD-1 and CTLA-4 Blockade in an SCLC Patient with Negative PD-L1 Expression on Biopsy: A Case Report
by: Marco Cefalì, et al.
Published: (2023-03-01)

Oncolytic Activity of a Chimeric Influenza A Virus Carrying a Human CTLA4 Antibody in Hepatocellular Carcinoma
by: Hao Yang, et al.
Published: (2022-04-01)

Intermittent dietary methionine deprivation facilitates tumoral ferroptosis and synergizes with checkpoint blockade
by: Ying Xue, et al.
Published: (2023-08-01)

The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3
by: Elly Marcq, et al.
Published: (2021-01-01)

TIM3 and CTLA4 immune checkpoint polymorphisms are associated with acute myeloid leukemia in Saudi Arabia
by: Mashael Alqahtani, et al.
Published: (2024-12-01)

Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
by: Dobrin Draganov, et al.
Published: (2021-03-01)

Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
by: Draganov, D, et al.
Published: (2022)